1x01 - Value Added Medicines: a patient-centric approach to healthcare
Conversations on the EU Pharma
Medicines for Europe
0 • 0 Ratings
🗓️ 23 March 2022
⏱️ 19 minutes
🧾️ Download transcript
Summary
Welcome to Conversations on EU Pharma!
‘Conversations on EU Pharma’ is the podcast created by Medicines for Europe that explores the off-patent medicines world.
In our very first episode, we will talk about Value Added Medicines (VAMs) to understand what benefits they can deliver to patients and the whole healthcare community.
Our guests will be Monica Fletcher OBE, FERS, FQNI Honorary Research Fellow from the University of Edinburgh and Maja Sercic, Policy & Science manager at Medicines for Europe.
Kate O’Regan, Communications & Stakeholder Relations Senior Manager from Medicines for Europe will be our host.
If this episode piques your curiosity, visit our website for more information on VAMs: https://www.medicinesforeurope.com/value-added-medicines /
To learn more about the benefits of VAMs for patients with respiratory diseases, check Monica Fletcher‘s publications https://www.researchgate.net/profile/Monica-Fletcher and take a look at the Asthma UK Centre for Applied Research: https://www.ed.ac.uk/usher/aukcar and at BREATHE – The Health Data Research Hub for Respiratory Health, https://breathedatahub.com/
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Hello and welcome to conversations on EU pharma. |
| 0:11.8 | My name is Cato Regan and I will be the host of the discussion. |
| 0:15.4 | Today I'm really happy to be discussing value-added medicines with two experts in the field. |
| 0:20.4 | The first is Monica Fletcher, |
| 0:22.1 | OBE, who works with the University of Edinburgh. Hello, Monica. Hi there, Kate. And our second |
| 0:28.2 | expert here today is Maya Surchich, who works at Medicines for Europe and leads our sector group |
| 0:34.1 | and our work on value-added medicines. Hi, Maya. Hi, Kate. Hi, Monica. Hi. So as I mentioned, |
| 0:40.6 | we're here today to discuss value-added medicines, but maybe Maya, can I ask you, what are they? Can you explain |
| 0:46.9 | a bit the concept to us? Yes, sure, Kate. So when we talk about value-added medicines, |
| 0:53.5 | we talk about taking something that already |
| 0:56.7 | exists, so well-known medications, existing molecules, and then rethink, reinward or |
| 1:05.3 | optimize their use. |
| 1:07.7 | So what we are doing here is applying continuous innovation approaches. |
| 1:13.1 | So sort of step-by-step innovation. |
| 1:16.3 | Yeah, Greece. |
| 1:16.8 | And Monica, does this sort of idea resonate with you? |
| 1:20.5 | Oh, yes, absolutely. |
| 1:21.8 | Whether it's a completely new system of delivery, |
| 1:25.1 | whether it's repurposing a medicine that we've had for many, many years, |
| 1:29.5 | I think this is just so important moving forward that, you know, where does innovation stop and |
| 1:35.2 | start here along the cycle? It's not necessary inventing new medicines. It's perhaps how we deliver |
| 1:40.9 | them and how we actually set that in the context of where we are today |
... |
Transcript will be available on the free plan in -1104 days. Upgrade to see the full transcript now.
Disclaimer: The podcast and artwork embedded on this page are from Medicines for Europe, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medicines for Europe and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.